MLI Certified

On-Demand Activities

Therapeutics Areas
Learner Specialties
Expires After
Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients
Treatment for R/R MCL is complicated, as the disease typically presents in elderly, unfit patients; however, emerging targeted therapy options have shown great promise based on excellent results in clinical trials. In this activity, a taped version of the live symposium at the 17th Annual International Conference on Malignant Lymphoma, expert faculty present therapeutic options, established by evidence-based practice guidelines, for patients with R/R MCL. Symposium learners voted on patient demographics and parameters such as treatment, dosing frequency, and adverse events. The experts crafted their lecture to follow thheir suggestions allowing the case studies to reflect the patients the learners see. The activity concludes with a discussion on engagement between healthcare providers and patients to improve clinical outcomes.
Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis
In on-demand activity, Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, learn from expert faculty, Jeanne Palmer, MD and Jennifer Andres, APRN, FNP, MSN as they discuss Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, to effectively identify how JAK inhibitors and emerging treatments for myelofibrosis (MF) can optimize clinical outcomes and patient quality of life (QOL). Gain expert insights from enduring online program focuses on patient risk and drug mechanisms of action for effective treatment and management, gaps in MF care that influence patient QOL, disease- and treatment-related adverse events, trust with patients to improve outcomes and QOL, as well as shared decision-making and the unique role of multidisciplinary teams.
Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies
In this second episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty on how to select CAR T-cell and bispecific antibody treatment regimens for NHL according to the latest clinical evidence including safety and efficacy data in accordance with clinical guidelines. Additionally, expert faculty will discuss how to best identify patients who are candidates for CAR T-cell or bispecific antibody therapies as well as how to evaluate the potential of bridging therapy in patients awaiting CAR T-cell therapy. Finally, expert faculty will review treatment-related toxicities with strategies and educational tools that can be used to prevent, monitor, and manage adverse events. This episode will conclude with a discussion between expert faculty and a special guest, Caitlin Murphy, DNP.
Shared Decision Making
It is a process that fosters shared decision making that includes exploring and comparing the benefits, harms, and risks of each health care option through meaningful dialogue about what matters most to the patient. The doctor and patient need to use evidence-based information while working together to make the best possible treatment decisions.
New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.
Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care
In this third episode, “Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” join expert faculty and special guest, Caitlin Murphy, DNP to discuss community-based practices for the treatment of NHL and HL. This episode will focus on how to best evaluate patients for and increase participation in clinical trials. Additional conversations will revolve around assessing patient quality of life, recognizing social determinants of health that impact patient care, and recognizing healthcare barriers and inequities in your own patient population. This episode will conclude with a conversation about misperceptions for CAR T-cell therapy and how to best coordinate care for patients receiving either CAR T-cell therapy or bispecific antibody therapy.
The Value and Importance of Not Postponing Joy
Educating your advanced cancer patients about the value and importance of not postponing joy. There is a tendency to avoid discussing the future, too far in advance, with your patients with advanced disease. The sooner we bring up the topic of not postponing joy, the better however. Patients may even say that they are planning on a family vacation to Disney World in 2 years. Your thoughts immediately go to estimating when she will be likely too ill to go but may not be verbalizing this to her. You don’t want to take away hope and burst that bubble. It however isn’t fair to the patient to be assuming that no response from you regarding such an announcement, or worse, saying that this sounds great, is doing her an injustice. Additionally, though she may still be living in two years and technically able to go to Disney World, she may very well be spending her time in the hotel room and not enjoying herself and her children/grandchildren doing park activities. Her goal wasn’t to be in a bed too weak to partake of this important family adventure. This is why a discussion about “Don’t Postpone Joy” is so important. It fits for many clinical settings too.
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies / Activity 1
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in metastatic NSCLC (mNSCLC) and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 2 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice to apply the evidence to real-world patient cases!
Communicating with Family, Friends and Coworkers
Advising Patients How To Communicate Information to Others about their Cancer Diagnosis and Treatment. What you will learn from this module: Learn about cancer patients feel isolated from their usual social community. Understand a cancer patients frustrations with lay people who insist on giving them advice how to manage their cancer. Learn about some metastatic breast cancer patients feeling angry when questioned by acquaintances if they “really have cancer.” Learn about the assumptions society makes regarding physical appearance of someone with cancer. Learn about the societal stigma associated with some cancers. Understand that barriers can exist within certain races regarding sharing cancer information with anyone, even family.
The Difference Between Palliative and Hospice Care
The Difference between Palliative Care and Hospice that result in Barriers to Care. What you will learn from this module:   Learn the assumptions and perceptions patients and their families have about the purpose of transitioning to hospice care. Understand the myths associated with agreeing to receive palliative care. Understand that palliative care stands alone and should be part of a patient’s care from the beginning when they are diagnosed with advanced cancer. Learn the barriers to implementing palliative care. Learn the value of palliative care when delivering patient centered care. Learn about how palliative care is also part of hospice care.
Supporting the Family Caregiver
The role of the treatment team in supporting the family caregiver. What you will learn from this module: Learn the physical and emotional needs of the caregiver managing the patient at home. Understand the stress and challenges loved ones face while caregiving. Realize that oftentimes the oncologist’s focus is solely on the patient and not on the loved one who is caregiving. Understand that a caregiver for a patient might be someone outside of the family- like a close friend. This can be due to the lack of family members, dysfunctional family dynamics, or ages of family members (young and old).
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Screening and Management of OSA
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape. Explore the 3-part on-demand series, Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health. This collaborative effort, in conjunction with local AAFP Chapter meetings, provides expert guidance and clinical best practices for screening, managing, monitoring, and treating patients with OSA
Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.
The Evolution of HCT, Part 4: Addressing Barriers
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 4 in a 5-part series, examining major barriers to HCT and ways to overcome them.
The Importance of Being Honest
Of everything we do for our patients, the most important thing we can give them is honesty. What you will learn from this module: Learn that being honest with patients about their disease and its prognosis is very important for patients to know so they can plan out the remainder of their lives. Honesty doesn’t take away hope; it helps the patient move through phases of hope. 50% of the time, doctors do not disclose the patients’ actual prognosis. Patients do not understand or know the difference between palliative chemotherapy and active chemotherapy treatments, unless they are told.  Teaching patients to be optimistic for as long as it is realistic, while having an end of life plan in place should be our mantra. Avoidance of honesty may be linked to an oncologist’s feelings of believing they have failed the patient by not being able to save or sustain their life.
Metastatic Breast Cancer Retreats: Value to the Patient and Your Multidisciplinary Team
Why Your Patients Should Attend a Metastatic Breast Cancer Retreat and the Value it also provides to you and your multi-disciplinary team. This video will demonstrate some of the activities that take place at a MBC retreat and the lessons learned from them.
Build Your Own Case Study | Redefining MASLD/MASH Care: Personalized Strategies for Assessment, Diagnosis and Management
Health Care Providers (HCPs) in the endocrinology specialty setting are challenged to be knowledgeable of the pathophysiology of MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) and its associated risk factors, as well as feel confident around how and when to order noninvasive diagnostic tests to prevent the emergence of more severe complications and stay on top of current guidelines and emerging treatment options.
Advances in Non-Hodgkin Lymphoma Care: Navigating New and Emerging Treatments
In this first episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty about unmet needs for patients with NHL based on an understanding of disease- and patient-related characteristics. Additionally, learn how to best assess eligible patients among new and emerging CAR T-cell and bispecific antibody therapies. Expert faculty will also discuss both the mechanisms of action of CAR T-cell and bispecific antibodies. This episode will conclude with a patient case study, which will consist of a dialogue between faculty.
Delivering Patient Centered Care
Patient-centered care is a model of care that respects the patient’s experience, values, needs and preferences in the planning, coordination and delivery of care. A central component of this model is a therapeutic relationship between the patient and the team of healthcare professionals. The implementation of a patient-centered care model has been shown to contribute to improved outcomes for patients, better use of resources, decreased costs and increased satisfaction with care. This article provides an overview of the barriers to providing patient-centered care and identifies strategies that can be implemented to overcome them.
Lessons Learned from Your Patient's Family After Their Loved One Has Died
Our time spent with patients and their families should not end with the transfer of the patient to hospice care. The patient may even resist such a transfer, feeling abandoned by their medical oncology team. Treatment for treatment’s sake is really bad medical care. Doing an effective job of preparing the patient and family for end of life needs to be the ultimate goal as treatments begin to no longer work. Due to having no contact with families after the patients have died results in losing teaching moments for the team that provided her breast cancer treatment. There is great value in incorporating the family’s needs and understanding into the treatment planning process from the beginning so they are better prepared at the end of her life and beyond.
The Evolution of HCT, Part 1: Basics and Outcomes
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 1 in a 5-part series, including the series introduction, basics of HCT, and major advances in HCT outcomes over time.
Understanding the Impact of Weight on T2D Outcomes
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Time Well Spent: Treating Obesity and Diabetes
Community Collective: Time Well Spent – Navigating the Challenges of Treating Obesity and Diabetes is an educational curriculum designed for rural primary care clinicians to enhance outcomes for individuals with obesity through improved diagnosis and use of therapy options to treat type 2 diabetes (T2D).
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided with patient clinical presentation and other relevant factors including age, time and aggressiveness of relapse, social history, genetic profiling/molecular testing results, cytogenetic risk factors, disease subtype, comorbidities, and prior therapies in order to make appropriate treatment decisions. Expert faculty will discuss participant selection of treatments, sequencing considerations, and drug-related toxicities. The activity will conclude with a discussion on how to develop strategies to assist patients with coordinated care and long-term disease management after the receipt of CAR T-cell therapy. This ancillary educational activity is derived from the 2024 ASCO Annual Meeting, originally held on May 31, 2024
Scroll to Top